Bioanalytical data in decision making: discovery and development.
1. Bioanalysis is traditionally associated with the development phase of drugs; its use in discovery programmes is often ignored but can have a major impact. 2. Pharmacokinetic studies conducted in conjunction with pharmacology screening can provide additional information to that considered in conventional structure activity relationships. Such factors as half-life and bioavailability can be critical in designing improved drugs. 3. Analytical methods in discovery programmes may differ from those used in later development work: for instance bioassay allows a common assay system for a large number of project compounds. Moreover its use, when combined with conventional methods, such as h.p.l.c., allows active metabolites to be readily detected. 4. Bioanalytical data generated in discovery and pre-clinical programmes are a valuable guide to early clinical programmes. Plasma concentration-response data from these programmes can be compared with those obtained in man. Such comparisons are particularly valuable during the phase one-initial dose escalation study. To maximize this it is our practice to generate pharmacokinetic data between each dose increase.
Smith
D A
DA
Department of Drug Metabolism, Pfizer Central Research, Sandwich, Kent, UK.
Beaumont
K
K
Cussans
N J
NJ
Humphrey
M J
MJ
Jezequel
S G
SG
Rance
D J
DJ
Stopher
D A
DA
Walker
D K
DK
D000818:Animals; D017322:Clinical Trials, Phase II as Topic / Q000379:methods; D003627:Data Interpretation, Statistical; D003657:Decision Making; D015195:Drug Design; D004341:Drug Evaluation / Q000379:methods*; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D006801:Humans; D010599:Pharmacokinetics